Communications


Synthesis of Heterocyclic Baicalein Derivatives


Ki-Jun Hwang, Kwang-Jin Cho, and Beom-Tae Kim^{†,*}

Department of Chemistry, College of Natural Science, [†]Research Center of Bioactive Materials, Chonbuk National University, Jeonju 561-756, Korea. ^{*}E-mail: bkim002@jbnu.ac.kr Received January 6, 2013, Accepted March 6, 2013

Key Words : Baicalein, Heterocyclic baicalein derivatives

Flavonoids are widely distributed in plant kingdom and they belong to the secondary metabolites of plants. Their diverse structures (Figure 1) combined with variety of biological activities such as *anti*-cancer, *anti*-inflammatory, *anti*-viral, apoptosis and *anti*-oxidation drew much attention during last decades.¹⁻⁴ The importance of Baicalein derivatives in terms of their biological activities was more clearly exemplified by recent reports. Thus, Chung *et al.*⁵ reported that Baicalein **4** affects the pharmacokinetics of Tamoxifen which is the agent of choice for treating and preventing breast cancer. Also more recently Kim *et al.*⁶ reported the suppressing effect for the NF- κ B signaling pathway for the Baicalein derivatives. So, it was envisioned that the expansion of chemical synthesis of Baicalein derivatives containing a heterocyclic ring is highly warranted. Since a bioisosterism^{7,8} is a lead modification approach to attenuate toxicity and/or improve the biological properties of the compounds, we decided to substitute the benzene moiety of 2-position of Baicalein **4** by a heterocyclic ring such as thiophene or furan to test their biological activities. Furthermore Kim *et al.*⁹ reported a practical synthetic method of Baicalein **4** due to the interests from many research groups





Scheme 1. Reagents and reaction conditions: (a) cat. DMAP, toluene, 110 °C, 20 min; (b) 1.1 eq. BF₃·Et₂O, 110 °C, 2 h, 60-75% from 7; (c) cat. I₂, DMSO, 120 °C, 2 h, 75-92%; (d) 0.1 eq. Tetrabutylammonium iodide (TBAI), 47% HBr, reflux, 18 h, 65-74%.

 Table 1. Analytical data for the heterocyclic Baicalein derivatives 12



Entry	R	¹ H-NMR (CD ₃ OD, 400 MHz)	¹³ C-NMR (CD ₃ OD, 100 MHz)	mp (°C)	ESI-MS (<i>m</i> / <i>z</i>)
1	S X	δ 6.50 (s, 1H), 6.79 (s, 1H), 7.27 (m, 1H), 7.95 (d, <i>J</i> = 5.2 Hz,1H), 8.00(d, <i>J</i> = 3.2 Hz, 1H)	δ 93.79, 102.82, 116.14, 129.00, 129.38, 129.66, 131.87, 134.00, 147.08, 149.32, 153.50, 158.91, 181.58	dec. > 200	277.2 (M+1)
2	Sr. Sr.	δ 6.56 (s, 1H), 6.81 (s, 1H), 7.74 (m, 2H), 8.42 (m, 1H)	δ 93.91, 104.00, 104.15, 125.49, 128.29, 128.35, 129.22, 133.52, 147.02, 149.57, 153.46, 159.51, 182.20	dec. > 200	277.3 (M+1)
3	No Xi	δ 6.40 (s, 1H), 6.42 (s, 1H), 6.60 (dd, <i>J</i> = 3.6, 3.3 Hz, 1H), 7.14 (d, <i>J</i> = 3.6 Hz, 1H), 7.69 (d, <i>J</i> = 3.2 Hz, 1H)	δ 93.01, 103.12, 105.84, 113.82, 114.63, 130.79, 147.36, 147.80, 148.09, 151.59, 154.79, 157.26, 183.89	179	261.4 (M+1)
4	Contraction of the second seco	δ 6.43 (s, 1H), 6.52 (s, 1H), 6.91 (d, <i>J</i> = 6.2 Hz, 1H), 7.66 (d, 1H), 8.26 (s, 1H)	δ 94.95, 104.95, 108.59, 121.50, 130.47, 130.61, 137.82, 145.19, 146.29, 151.89, 154.73, 161.15, 184.00	dec. > 200	261.3 (M+1)

in testing the activities of Baicalein 4. So, with the important concept of heterocyclic Baicalein derivatives due to the possible bioactivities exhibited by them and the synthetic technology to construct the Baicalein ring system in hand, we carried out synthetic efforts to prepare several heterocyclic Baicalein derivatives 12 (Scheme 1).

The key intermediate 8 were prepared by Knovenegal condensation of commercially available aldehydes with malonic acid followed by chlorination of the corresponding acids with thionyl chloride with no incidence. Condensation of 3,4,5-trimethoxyphenol 7 with acid halides 8 provided compounds 9 in almost quantitative yields. It was noticed that the addition of catalytic amount of DMAP is crucial for good results. Without isolation of the compounds 9 (the completion of reaction is checked by TLC), the reaction mixture was subjected to Fries rearrangement by adding 1.1 eq. of BF₃·Et₂O and then refluxing the reaction mixture for 2h followed by aqueous workup to get compound 10 in 60-75% yields. Ring closure of chalcones 10 to flavonoids 11 was accomplished by the published procedure⁹ in 75-92% yields. The final step of demethylation on flavonoids 11 was carried out successfully by the published procedure¹⁰ in 65-74% purified yields. The analytical data for the final compounds 12 were summarized in Table 1.

As a conclusion we prepared several Baicalein derivatives containing thiophene and furan ring, and their expected biological activity test is waiting.

Acknowledgments. This work was supported by research funds of Chonbuk National University in 2011.

References

- Kim, M. J.; Han, J. M.; Jin, Y. Y.; Bang, M. H.; Chung, H. G; Choi, M. S.; Lee, K. T.; Sok, D. E.; Jeong, T. S. *Arch. Pharm. Res.* 2008, *31*, 429.
- Ciesielska, E.; Wolszczak, M.; Gulanowski, B.; Szalawska, A.; Kochman, A.; Metodiewa, D. *In vivo.* 2004, *18*, 497.
- Wang, J.; Yu, Y.; Hashimoto, F.; Sakata, Y.; Fujii, M.; Hou, D. X. Int. J. Mol. Med. 2004, 14, 627.
- Liu, J. D.; Huang, T. S.; Chung, W. F.; Lu, F. J. Int. J. Cancer. 2003, 106, 559.
- Chang, L.; Kim, M. H.; Choi, H. S.; Choi, J. S. Arch. Pharm. Res. 2011, 34, 1965.
- Kim, D. H.; Yun, C. H.; Kim, M. H.; Kumar, C. N.; Yun, B. H.; Shin, J. S.; An, H. J.; Lee, Y. H.; Yun, Y. D.; Rim, H. K.; Yoo, M. S.; Lee, K. T.; Lee, Y. S. *Bioorganic. Med. Chem. Lett.* **2012**, *22*, 700.
- Blair, J. B.; Kanthasamy, A.; Lucaites, V. L.; Nelson, D. L.; Nichols, D. E. J. Med. Chem. 1999, 42, 1106.
- Hwang, K. J.; Lee, T. S.; Kim, K. W.; Kim, B. T.; Lee, C. M.; Park, E. Y.; Woo, R. S. Arch. Pharm. Res. 2001, 24, 270.
- Kim, S. H.; Sohn, D. W.; Kim, Y. C.; Kim, S. A.; Lee, S. K.; Kim, H. S. Arch. Pharm. Res. 2007, 30, 18.
- Dao, T. T.; Chi, Y. S.; Kim, J. S.; Kim, H. P.; Kim, S. H.; Park, H. Bioorg. Med. Chem. Lett. 2004, 14, 1165.